Literature DB >> 16645132

Model of hospital-supported discharge after stroke.

Claus Rydahl Torp1, Sonja Vinkler, Kirsten Damgaard Pedersen, Finn Rønholt Hansen, Torben Jørgensen, Ingrid Willaing, Jens Olsen.   

Abstract

BACKGROUND AND
PURPOSE: Readmission rate within 6 months after a stroke is 40% to 50%. The purpose of the project was to evaluate whether an interdisciplinary stroke team could reduce length of hospital stay, readmission rate, increase patient satisfaction and reduce dependency of help.
METHODS: One hundred and ninety-eight patients with acute stroke were randomized into 103 patients whose discharge was supported by an interdisciplinary stroke team and 95 control patients who received standard aftercare. Baseline characteristics were comparable in the 2 groups. The patients were evaluated after 6 and 12 months regarding functional status and need for help.
RESULTS: Length of hospital admission was insignificantly shorter in the intervention compared with the control group (35.2 versus 39.8 days). There was no significant difference in readmission, GP-visits, and primary health care services. Furthermore, there was no significant difference in functional scores or patient satisfaction.
CONCLUSIONS: In this setting we could not show benefit of an interdisciplinary stroke team supporting patients at discharge perhaps because standard aftercare was very efficient already.

Entities:  

Mesh:

Year:  2006        PMID: 16645132     DOI: 10.1161/01.STR.0000221793.81260.ed

Source DB:  PubMed          Journal:  Stroke        ISSN: 0039-2499            Impact factor:   7.914


  2 in total

Review 1.  Early supported discharge services for people with acute stroke.

Authors:  Peter Langhorne; Satu Baylan
Journal:  Cochrane Database Syst Rev       Date:  2017-07-13

2.  Self-perceived postural balance correlates with postural balance and anxiety during the first year after stroke: a part of the randomized controlled GOTVED study.

Authors:  Lena Rafsten; Anna Danielsson; Katharina S Sunnerhagen
Journal:  BMC Neurol       Date:  2020-11-09       Impact factor: 2.474

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.